Literature DB >> 21670191

Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Jill M Butterfield1, Nimish Patel, Manjunath P Pai, Thomas G Rosano, George L Drusano, Thomas P Lodise.   

Abstract

While current data indicate only free (unbound) drug is pharmacologically active and is most predictive of response, pharmacodynamic studies of vancomycin have been limited to measurement of total concentrations. The protein binding of vancomycin is thought to be approximately 50%, but considerable variability surrounds this estimate. The present study sought to determine the extent of vancomycin protein binding, to identify factors that modulate its binding, and to create and validate a prediction tool to estimate the extent of protein binding based on individual clinical factors. This single-site prospective cohort study included hospitalized adult patients treated with vancomycin and with a vancomycin serum concentration determination available. Linear regression was used to predict the free vancomycin concentration (f[vanco]) and to determine the clinical factors modulating vancomycin protein binding. Among the 50 patients in the study, the mean protein binding was 41.5%. The strongest predictor of f[vanco] was the total vancomycin concentration (total [vanco]), and this was modified by dialysis and total protein of ≥6.7 g/dl as covariates. The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 × total [vanco] - {0.067 × total [vanco] × D} - {0.071 × total [vanco] × TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is ≥6.7 g/dl or 0 if total protein is <6.7 g/dl. The R(2) of the final prediction model was 0.959 (P < 0.001). Validation of our model was performed in 13 patients, and the predictive performance was highly favorable (R(2) was 0.9, and bias and precision were 0.18 and 0.18, respectively). Prediction models such as ours can be utilized in future pharmacokinetics and pharmacodynamics studies evaluating the exposure-response profile and to determine the pharmacodynamic target of interest as it relates to the free concentration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670191      PMCID: PMC3165330          DOI: 10.1128/AAC.01674-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

2.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Vancomycin serum protein binding determination by ultrafiltration.

Authors:  B H Ackerman; E H Taylor; K M Olsen; W Abdel-Malak; A A Pappas
Journal:  Drug Intell Clin Pharm       Date:  1988-04

5.  Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections.

Authors:  Karine Berthoin; Els Ampe; Paul M Tulkens; Stephane Carryn
Journal:  Int J Antimicrob Agents       Date:  2009-09-26       Impact factor: 5.283

6.  Effect of protein binding on antibiotic activity in vivo.

Authors:  D J Merrikin; J Briant; G N Rolinson
Journal:  J Antimicrob Chemother       Date:  1983-03       Impact factor: 5.790

7.  Vancomycin protein binding in patients with infections caused by Staphylococcus aureus.

Authors:  L M Albrecht; M J Rybak; L H Warbasse; D J Edwards
Journal:  DICP       Date:  1991 Jul-Aug

8.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin.

Authors:  E M Bailey; M J Rybak; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries.

Authors:  H Z Zokufa; L D Solem; K A Rodvold; K B Crossley; J H Fischer; J C Rotschafer
Journal:  J Burn Care Rehabil       Date:  1989 Sep-Oct

10.  Protein binding and serum bactericidal activities of vancomycin and teicoplanin.

Authors:  R S Dykhuizen; G Harvey; N Stephenson; D Nathwani; I M Gould
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  28 in total

1.  Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.

Authors:  Anthony M Nicasio; Jürgen B Bulitta; Thomas P Lodise; Rebecca E D'Hondt; Robert Kulawy; Arnold Louie; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model.

Authors:  Razieh Kebriaei; Seth A Rice; Kyle C Stamper; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.

Authors:  Matthew P Rowan; Krista L Niece; Julie A Rizzo; Kevin S Akers
Journal:  Adv Wound Care (New Rochelle)       Date:  2017-02-01       Impact factor: 4.730

4.  Optimizing the Use of Antibacterial Agents in the Neonatal Period.

Authors:  Joseph B Cantey
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

5.  Treatment of severe drug reactions by hemodialysis.

Authors:  Rokea A El-Azhary; Michael Z Wang; Ashley B Wentworth; LaTonya J Hickson
Journal:  Int J Dermatol       Date:  2017-11-22       Impact factor: 2.736

6.  Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.

Authors:  Laurent Bourguignon; Yoann Cazaubon; Guillaume Debeurme; Constance Loue; Michel Ducher; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  Antimicrobial distribution from local delivery depends on dose : a pilot study with MRI.

Authors:  Alex McLaren; Morgan B Giers; James Fraser; Luke Hosack; Michael R Caplan; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2014-11       Impact factor: 4.176

Review 8.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

9.  Factors impacting unbound vancomycin concentrations in neonates and young infants.

Authors:  Anne Smits; Steven Pauwels; Matthijs Oyaert; Nele Peersman; Isabel Spriet; Veroniek Saegeman; Karel Allegaert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-05-16       Impact factor: 3.267

Review 10.  Antimicrobial dosing in acute renal replacement.

Authors:  William H Fissell
Journal:  Adv Chronic Kidney Dis       Date:  2013-01       Impact factor: 3.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.